Drug Approval | July 10, 2024
Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin’s Pithampur facility in India
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
The trademark rights for these brands will be transferred to Lupin by March next year.
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
